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Defining the metabolic programs that underlie stem
cell maintenance will be essential for developing
strategies tomanipulate stem cell capacity. Mamma-
lian hematopoietic stem cells (HSCs) maintain cell
cycle quiescence in a hypoxic microenvironment. It
has been proposed that HSCs exhibit a distinct
metabolic phenotype under these conditions. Here
we directly investigated this idea using metabolomic
analysis and found that HSCs generate adenosine-
50-triphosphate by anaerobic glycolysis through a
pyruvate dehydrogenase kinase (Pdk)-dependent
mechanism. Elevated Pdk expression leads to active
suppression of the influx of glycolytic metabolites
into mitochondria. Pdk overexpression in glycol-
ysis-defective HSCs restored glycolysis, cell cycle
quiescence, and stem cell capacity, while loss of
both Pdk2 and Pdk4 attenuated HSC quiescence,
glycolysis, and transplantation capacity. Moreover,
treatment of HSCs with a Pdk mimetic promoted
their survival and transplantation capacity. Thus,
glycolytic metabolic status governed by Pdk acts
as a cell cycle checkpoint that modulates HSC quies-
cence and function.
INTRODUCTION
Stem cells are tissue-sustaining cells that generate differentiated
progeny and are resistant to external stresses (Zon, 2008; Seita
and Weissman, 2010). Although stem cells probably exhibitmetabolic characteristics allowing them to meet diverse energy
demands, it is not known whether their metabolic phenotype
differs from that of transiently amplifying progenitors and
terminally differentiated cells and, if so, how metabolic pheno-
types directly define stem cell identity (Suda et al., 2011). Cells
generate adenosine-50-triphosphate (ATP), the major currency
for energy-consuming reactions, through central carbon
metabolism, including glycolysis and mitochondrial oxidative
phosphorylation (OXPHOS). The mammalian HSC system is
maintained by self-renewal of quiescent long-term (LT)-HSCs
and subsequent generation of short-term (ST)-HSCs, multipo-
tent progenitors (MPPs), and various lineage-restricted proge-
nies (Zon, 2008; Seita and Weissman, 2010). Adult LT-HSCs
are maintained in a hypoxic state in the bone marrow (BM) niche
(Parmar et al., 2007; Takubo et al., 2010). LT-HSCs maintain cell
cycle quiescence through precise regulation of levels of hypoxia-
inducible factor-1a (HIF-1a), a transcription factor responsive to
cellular and systemic hypoxia (Takubo et al., 2010).
LT-HSCs, which exhibit fewer mitochondria than progenitors
(Kim et al., 1998; Simsek et al., 2010; Norddahl et al., 2011),
are hypothesized to utilize anaerobic metabolism in the hypoxic
endosteal zone. Although the ratio of ATP generation to glucose
consumption under anaerobic glycolysis is inefficient compared
with that supported by OXPHOS, the rate of ATP production
under hypoxia potentially increases 100-fold compared to that
supported by mitochondrial energy production under normoxia
(Voet and Voet, 2010). HSCs are particularly sensitive to oxida-
tive stress and show low endogenous ROS levels. Aberrant
ROS generation could abrogate various stem cell properties
including cell cycle quiescence, self-renewal, survival, andmulti-
lineage differentiation capacity in HSCs (Miyamoto et al., 2007;
Kobayashi and Suda, 2012). Because various mutant mice
defective in LT-HSCmaintenance display a wide range of bioen-
ergetic defects in vivo, achieving a stable metabolic state inCell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc. 49
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HSC Metabolic Checkpoint by PdkLT-HSCs is probably important for their maintenance (Liu et al.,
2009; Nakada et al., 2010; Gurumurthy et al., 2010; Gan et al.,
2010; Sahin et al., 2011). Recently, Simsek et al. reported that
LT-HSCs show higher glycolytic capacity than do cells in whole
BM, which consists primarily of lineage marker+-differentiated
cells (Lin+ cells) (Simsek et al., 2010). This activity is regulated
by Cripto-GRP78 signaling activated by HIF-1a (Miharada
et al., 2011). However, it remains unclear whether these meta-
bolic characteristics are common in primitive hematopoietic
cells such as LT-HSCs and progenitors and required for their
maintenance.
In this study, we addressed the proposed ‘‘metabolic stem-
ness’’ of HSCs, namely glycolytic activation, using metabolo-
mics and genetics. During glycolysis, glucose is converted to
pyruvate and then anaerobically to lactate or aerobically to
acetyl-CoA for use in mitochondrial metabolism. The conversion
of pyruvate to acetyl-CoA is catalyzed by pyruvate dehydroge-
nase (PDH), whose activity is suppressed by phosphorylation
by PDH kinases (Pdks) (Harris et al., 2002). We observed that
LT-HSCs show HIF-1a-mediated Pdk activation, resulting in
maintenance of glycolytic flow and suppression of the influx of
glycolytic metabolites into mitochondria. Also, a glycolytic
metabolic state was shown to promote LT-HSC cell cycle quies-
cence, an activity that could potentially be exploited to regulate
the cell cycle in those cells in vitro and in vivo. In mice, loss of
Pdk2 and Pdk4 resulted in defective maintenance of cell cycle
quiescence and transplantation capacity and altered glycolytic
metabolic properties in LT-HSCs. Treatment of LT-HSCs with
a competitive inhibitor of PDH promoted maintenance of trans-
plantation capacity in vitro. These observations suggest that
Pdk-mediated antagonism of mitochondrial metabolism com-
prises a checkpoint required to establish a metabolic state
favoring cell cycle quiescence of LT-HSCs.
RESULTS
Metabolomic Profiling of Central Carbon Metabolism
in LT-HSCs and Their Progeny
To define specific metabolic characteristics of hypoxic LT-
HSCs, we performed metabolome analyses with capillary
electrophoresis time-of-flight mass spectrometry (CE-TOFMS)
(Soga et al., 2003, 2006; Shintani et al., 2009) using at least
1 3 106 murine BM LT-HSCs (CD34Flt3 Lineage marker
Sca-1+ c-Kit+; CD34Flt3 LSK cells) and their progeny,
including ST-HSCs (CD34+Flt3 LSK cells), MPPs (CD34+Flt3+
LSK cells), myeloid progenitors (MPs; Lin c-Kit+ Sca-1 cells),
and differentiated hematopoietic cells (Gr-1/Mac-1+ myeloid
cells, CD4/CD8+ T cells, and B220+ B cells) to assess levels of
intracellular metabolites functioning in central carbon metabo-
lism. We replicated the analysis and show one representative
result in Figure 1A and Figure S1A available online (Figure 1A is
an extract of Figure S1A). Notably, fructose 1,6-bisphosphate
(F1,6BP), a product of the rate-limiting step of glycolysis cata-
lyzed by phosphofructokinase-1 (Pfk-1), was observed only in
LT-HSCs and ST-HSCs (Figures 1A and S1A). Because F1,6BP
is a strong allosteric activator of pyruvate kinase (PK) (Voet and
Voet, 2010), LT-HSCs probably support glycolytic metabolism
required to produce PK-dependent ATP. Because low levels of
the Pfk-1 substrate fructose-6-phosphate were also observed50 Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc.in LT-HSCs, the rate-limiting Pfk-1 reaction is probably activated
in LT-HSCs (Figures 1A and S1A). In addition, pyruvate, a by-
product of PK-dependent ATP generation, accumulated to
high levels in LT-HSCs (Figures 1A and S1A), while levels of
phosphoenolpyruvate, a PK substrate, remained low (Figures 1A
and S1A). Mitochondrial OXPHOS is fueled by the tricarboxylic
acid (TCA) cycle. Among TCA cycle-related metabolites, 2-oxo-
glutarate (2-OG) and both acetyl-CoA and succinyl-CoA were
not detected in any hematopoietic fraction (Figure S1A). In
support of metabolomics profiling data shown in Figures 1A
and S1A, we found that various glycolytic enzymes were more
highly expressed in LT-HSCs than in progenitors or terminally
differentiated cells (Figure S1B), suggesting that LT-HSCs utilize
glycolysis for energy generation (Voet and Voet, 2010).
Interestingly, LT-HSC ATP levels were lowest among various
primitive hematopoietic cell fractions in the BM (Figure 1B).
The Side Population (SP) phenotype of LT-HSCs is marked by
expression of the ATP-dependent transporter Bcrp1 (Goodell
et al., 1996, 1997; Zhou et al., 2001) and maintained by intracel-
lular ATP production. The SP phenotype of normal LT-HSCs was
sensitive to treatment with the glycolytic inhibitor 2-deoxy-D-
glucose (2-DG) (Figure 1C). Treatment of BM mononuclear cells
(MNCs) with the respiration inhibitor sodium azide (NaN3), even
at concentrations (20 mM) sufficient to inhibit OXPHOS, moder-
ately reduced SP phenotypes in LT-HSCs (Figure 1C). Glucose
uptake by cells from primitive fractions including LT- or ST-
HSCs or MPPs was higher than that seen in myeloid progenitor
or lineage marker+ fractions (Figure 1D). The activity of pyruvate
kinase, which catalyzes an ATP-generating step in glycolysis,
was highest in LT-HSCs among various BM fractions (Figure 1E).
Overall, these observations suggest that only LT-HSCs, rather
than transiently amplifying progenitors or terminally differenti-
ated cells, can survive independent of mitochondrial energy
generation, possibly through suppression of the PDH-E1a
subunit by Pdk-dependent phosphorylation (depicted schemat-
ically in Figure 2A). Expression of all murine Pdk family members
(Pdk1–Pdk4) (Harris et al., 2002)was high in LT-HSCs (Figure 2B),
and PDH-E1awas more highly phosphorylated in LT-HSCs than
in their differentiated progeny (Figures 2C and 2D). The oxygen
consumption rate (OCR) was lowest in LT-HSCs, dynamically
upregulated after their differentiation into ST-HSCs, and slightly
decreased in MPPs or MPs (Figure 2E). The higher OCR seen in
fractions other than LT-HSCs was probably maintained by mito-
chondrial oxygen consumption, as treatment with oligomycin,
which inhibits mitochondrial ATP synthase, clearly suppressed
the OCR in these cells (Figure 2E). These findings are in accord
with the idea that LT-HSCs survive in a hypoxic environment
and are less dependent on mitochondrial oxygen-consuming
metabolism than more differentiated cells (Figure 2E).
Loss of HIF-1a Alters Energy Metabolism in LT-HSCs
To determine whether a HIF-1a-dependent crucial checkpoint
maintains anaerobic metabolic stemness in LT-HSCs, we exam-
ined parameters relevant to metabolism in HIF-1aD/D LT-HSCs.
We found that HIF-1a deficiency was accompanied by de-
creased expression of various glycolytic enzymes in LT-HSCs
(Figure S2). Glucose uptake was identical at various differentia-
tion stages in HIF-1aD/D BM (Figure 3A), although an essential
glucose transporter, Glut1, was significantly downregulated in
Figure 1. Metabolic Profiling of Glycolytic Metabolism in HSCs and Their Progeny
(A) Quantification of metabolites in glycolytic metabolism based on CE-TOFMS analysis. Bar graphs for independent metabolites plotted in the glycolytic
metabolism map are (from left to right): long-term (LT)-hematopoietic stem cells (HSCs) (CD34Flt3 LSK cells; blue bars), short-term (ST)-HSCs (CD34+Flt3
LSK cells; red bars), multipotent progenitors (MPPs) (CD34+Flt3+ LSK cells; green bars), myeloid progenitors (MPs; Lin c-Kit+ Sca-1 cells; yellow bars), Gr-1/
Mac-1+ myeloid cells (purple bars), CD4/CD8+ T cells (sky blue bars), and B220+ B lymphocytes (black bars). Data are representative of two independent
experiments.
(B) Relative intracellular ATP concentrations in LT-HSC, ST-HSC, MPP, LKS, and Lin+ cells (mean ± SD, n = 6, *p < 0.001).
(C) Effects of NaN3 (open bars) or 2-DG (closed bars) treatment on the Side Population phenotype of the CD34
 LSK fraction at indicated concentrations (mean ±
SD, n = 4, *p < 0.05, **p < 0.0002).
(D) Relative glucose uptake by LT-HSC, ST-HSC, MPP, MP, and Lin+ cells (mean ± SD, n = 5).
(E) Relative PK activity in LT-HSC, ST-HSC, MPP, MP, and Lin+ cells (mean ± SD, n = 6, *p < 0.001).
See also Figure S1.
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HSC Metabolic Checkpoint by PdkHIF-1aD/D LT-HSCs (Figure S2). Glycolytic LDH activity in normal
LT-HSCs was higher than that seen in CD34+ LSK progenitors
(the sum of ST-HSCs plus MPPs) and was decreased in HIF-
1aD/D LT-HSCs (Figure 3B). We found that LT-HSCs release
lactate into the culture medium only under hypoxia and those
levels decrease in the case of HIF-1a deficiency (Figure 3C).
Because intracellular levels of lactate, a product of the LDH
reaction, in LT-HSCs and their differentiated progeny were
unchanged (Figures 1A and S1A), we conclude that LT-HSCs
probably rapidly release lactate generated by glycolysis into
the extracellular space. Intracellular pyruvate levels, which are
high in LT-HSCs (Figures 1A and S1A), were decreased byHIF-1a deficiency (Figure 3D). These data suggest that, in the
hypoxic niche, LT-HSCs suppress flux of glycolytic metabolites
into mitochondria for the TCA cycle and HIF-1aD/D LT-HSCs
show defective conversion of pyruvate to lactate, an activity
maintained through the suppression of PDH by Pdk. In support
of this, phosphorylation of the a subunit of PDH-E1 is attenuated
in HIF-1aD/D LT-HSCs (Figure 3E). Overall ATP production was
considerably decreased in HIF-1aD/D LT-HSCs compared to
HIF-1aD/D CD34+ LSK progenitors (Figure 3F), suggesting that
ATP production in the former is dependent on HIF-1a-dependent
glycolysis and that mitochondrial metabolism is suppressed by
Pdk. Overall mitochondrial mass in wild-type LT-HSCs wasCell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc. 51
Figure 2. Pdk-Mediated Metabolic Proper-
ties of LT-HSCs
(A) Schematic representation of the effect of Pdks
on energy metabolism.
(B) qPCR analysis of Pdk family members in
CD34 LSK, CD34+ LSK, Lin, or Lin+ fractions
from 12-week-old mice (mean ± SD, n = 4). Each
value was normalized to b-actin expression and is
expressed as fold induction compared to levels
detected in CD34 LSK samples (*p < 0.01).
(C and D) Immunocytochemical staining for
phosphorylated S293 (C) or S300 (D) residues of
PDH-E1a (green), Mitotracker DeepRed (red), and
DAPI (blue) in wild-type LT-HSC (CD34 Flt3
LSK), ST-HSC (CD34+ Flt3 LSK), MPP (CD34+
Flt3+ LSK), or MP (Lineage marker c-Kit+ Sca-1)
cells.
(E) Oxygen consumption rate in LT-HSC, ST-HSC,
MPP, and MP cells treated with or without oligo-
mycin (mean ± SD, n = 6) (*p < 0.001).
See also Figure S2.
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HSC Metabolic Checkpoint by Pdksmaller than that seen in wild-type CD34+ LSK progenitors (Fig-
ure 3G). In HIF-1aD/D LT-HSCs, mitochondrial volume and
expression of the mitochondrial respiratory component COX4-
1 (Fukuda et al., 2007) were higher than that seen in wild-type
LT-HSCs (Figures 3G and 3H). These data suggest that HIF-
1aD/D LT-HSCs exhibit decreased dependence on anaerobic
glycolysis and activate mitochondrial aerobic metabolism due
to loss of a metabolic checkpoint regulated by PDH-E1a subunit
phosphorylation status.
To directly analyze metabolic changes in HIF-1aD/D HSCs, we
analyzed the SP phenotype. Overall, the HIF-1aD/D LSK fraction
showed significant loss of the SP phenotype after treatment with
20 mMNaN3 (Figure S3A), suggesting that, in the case of HIF-1a
deficiency, compensatory mitochondrial aerobic metabolism
supports ATP production in the primitive hematopoietic fraction.
By contrast, LSK cells deficient in VHL, an E3 ubiquitin ligase
targeting HIF-1a (Semenza, 2010), showed significantly reduced
mitochondrial volume compared to wild-type LSK cells (Fig-
ure S3B). Because normal quiescent HSCs have relatively little
cytoplasm and contain few inactive mitochondria (Kim et al.,
1998) (Figure 3G), the decreased mitochondrial mass seen in
VHLD/D LSK cells suggests that active regulatory mechanisms
function in HIF-1a dose-dependent energy production in
primitive hematopoietic cells.52 Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc.HIF-1a Maintains Pdk Expression,
Glycolysis, and Transplantation
Capacity in LT-HSCs
The decreased glycolysis and activated
mitochondrial energy metabolism seen
in HIF-1aD/D LT-HSCs (Figure 3) suggest
that HIF-1a-dependent remodeling of
metabolic pathways by Pdk-mediated
antagonism of PDH activity occurs in
LT-HSCs. Notably, among Pdk family
members, Pdk2 and Pdk4 mRNA levels
were positively correlated with HIF-1a
expression in LT-HSCs (Figure 4A). Their
mRNA levels decreased in the case ofHIF-1a deficiency and increased in the presence of VHL
deficiency (Figure 4A). Increased Pdk mRNA levels were sup-
pressed by deletion of both HIF-1a and VHL (Figure 4A).
Exposure of LT-HSCs to hypoxia increased expression of
Pdk4 but not Pdk2 (Figure S4A), suggesting oxygen-dependent
and -independent roles for HIF-1a for the expression of these
two genes. To verify that Pdks function as HIF-1a effectors in
HSC maintenance, we transduced LT-HSCs or LSK cells with
retrovirus expressing Pdk2 or Pdk4 (Figures 4B and S4B).
Pdk misexpression (at mRNA levels 100- to 1,000-fold greater
than normal) by retrovirus-restored phosphorylation of the
PDH-E1a subunit in HIF-1aD/D LT-HSCs (Figure 4C) and
glycolytic activity in HIF-1aD/D LSK cells, as measured by
LDH activity (Figure 4D), and antagonized increased mito-
chondrial ROS generation seen under HIF-1a deficiency (Ta-
kubo et al., 2010) (Figure S4D). The number of Ki67+ cycling
cells also decreased in Pdk-transduced HIF-1aD/D LSK cells
(Figure 4E). For in vitro analysis of HSCs, we utilized the
SLAM marker to detect HSCs in the LSK population because
some LT-HSCs tend to express CD34 in vitro (Noda et al.,
2008). HIF-1aD/D cells cultured in hypoxic conditions could
not sustain an LT-HSC fraction, a deficiency rescued by the
introduction of Pdk2 or Pdk4 into HIF-1aD/D LSK cells (Figures
4F and 4G).
Figure 3. Loss of HIF-1a Alters HSC Energy Metabolism
(A) Relative glucose uptake by LT-HSC, ST-HSC, MPP, and MP cells from HIF-1a+/+ or HIF-1aD/D mice (mean ± SD, n = 4).
(B) LDH activity in CD34+ or CD34 LSK cells fromHIF-1a+/+ orHIF-1aD/Dmice (mean ±SD, n = 4). Arbitrary units (a.u.) were calculated as the value relative to LDH
activity in the HIF-1a+/+ CD34 LSK fraction (set to 100; *p < 0.01).
(C) Lactate production in CD34 LSK cells under normoxic (20% O2) or hypoxic (1% O2) conditions per ten thousand cells (mean ± SD, n = 4; *p < 0.01).
(D) Relative intracellular pyruvate concentrations in LT-HSCs from HIF-1a+/+ or HIF-1aD/D mice (mean ± SD, n = 4; *p < 0.01).
(E) Immunocytochemical staining for phosphorylated S293 residues of PDH-E1a (green), mitochondrial dye Mitotracker DeepRed (red), and DAPI (blue) in
HIF-1a+/+ or HIF-1aD/D LT-HSCs.
(F) Intracellular ATP concentration in CD34+ or CD34 LSK cells from HIF-1a+/+ or HIF-1aD/D mice (mean ± SD, n = 3; *p < 0.05).
(G) Relativemitochondrial mass (mitochondrial fluorescence/nuclear fluorescence) in individualHIF-1aD/DCD34+ or CD34 LSK cells (n = 50). Data are presented
as the mean ± SD (*p < 0.001).
(H) Immunocytochemical staining of CD34 LSK cells for COX4-1 (red) and TOTO-3 (blue).
See also Figure S3.
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HSC Metabolic Checkpoint by PdkTo test reconstitution capacity, we transplanted 3,000 GFP+-
HIF-1aD/D LSK cells into lethally irradiated Ly5.1 (CD45.1+)
congenic mice together with competitor BM (CD45.1+). Trans-
duced LSK cells in every group contained a similar number of
LT-HSCs, as assessed by flow cytometry (data not shown).
Twelve weeks after BM transplantation (BMT), HIF-1aD/D
LSK cells transduced with GFP virus showed significantly
decreased repopulation capacity, probably due to upregulation
of p16Ink4a/p19Arf in HIF-1aD/D LT-HSCs during transductionstress, as previously reported (Takubo et al., 2010). In contrast,
HIF-1aD/D LSK cells transduced with either Pdk2 or Pdk4
virus showed substantial chimerism and multilineage reconsti-
tution capacity in peripheral blood (PB) compared to control
HIF-1aD/D cells (Figure 4H and Figure S4E). These experiments
suggest that HIF-1a maintains substantial chimerism and multi-
lineage reconstitution capacity through upregulation of Pdk2
and Pdk4 despite expression of other HIF-a family members
(Figure S4C).Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc. 53
AD E
B
C
G
F
H
Figure 4. HIF-1a Maintains Pdk Expression, Glycolysis, and Transplantation Capacity in HSCs
(A) qPCR analysis of Pdk2 and Pdk4 expression in the LT-HSC fraction of 12-week-old HIF-1a+/+, HIF-1aD/D, VHLD/D BM, or HIF-1aD/D:VHLD/D BMmice (n = 4).
Values are normalized to b-actin expression and expressed as fold induction compared to levels detected in HIF-1a+/+ samples (mean ± SD, n = 4, *p < 0.01).
(B) Design of retroviral rescue of Pdk expression in HIF-1aD/D LSK cells.
(C) Immunocytochemical staining for phosphorylated S293 residues of PDH-E1a (green), Mitotracker DeepRed (red), and DAPI (blue) in HIF-1aD/D LT-HSCs
transduced with GFP, Pdk2, or Pdk4 retroviruses.
(D) Intracellular LDH activity in GFP virus-transducedHIF-1a+/+ LSK cells or inHIF-1aD/D LSK cells transduced with GFP, Pdk2, or Pdk4 retroviruses (mean ± SD,
n = 5, *p < 0.000001).
(E) Immunocytochemical assessment of Ki67+ in LSK cells transduced with Pdks for 48 hr on a HIF-1a+/+ or HIF-1aD/D background (mean ± SD, n = 5).
(F) CD150+CD41CD48 LSK cells after transductionwith GFP, Pdk2, or Pdk4 retroviruses and then 7 days of culture under hypoxia (mean ± SD, n = 3, *p < 0.05).
(G) Quantification of total cell number of CD150+CD41CD48 LSK cells analyzed in (F).
(H) PB chimerism ofHIF-1aD/D donor cells transduced with Pdk viruses at 1, 2, 3 and 4 months (M) after BMT (mean ± SEM, n = 5, *p < 0.05, **p < 0.02; compared
to HIF-1aD/D+GFP virus).
See also Figure S4.
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HSC Metabolic Checkpoint by PdkPdk2 and Pdk4 Are Essential for LT-HSC
Transplantation Capacity
To assess whether Pdk functions in LT-HSCmaintenance down-
stream of HIF-1a, we examined hematopoiesis of Pdk2/Pdk4
double knockout mice (Dunford et al., 2011; Jeoung et al.,
2006). Peripheral blood counts indicated that these Pdk2/:
Pdk4/ mice were mildly but significantly anemic compared
to control mice (Figure 5A). Various populations of differentiated
and undifferentiated cells in the BM, spleen, and thymus54 Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc.were unchanged in number in Pdk2/: Pdk4/ mice
(Figures S5A–S5E). Progenitor capacity of Pdk2/: Pdk4/
LSK cells, as assessed by the colony-forming capacity in semi-
solid methylcellulose plus cytokines, was identical to that of
control cells (Figure 5B), suggesting that steady-state hemato-
poiesis and progenitor capacity is maintained in Pdk2/:
Pdk4/ mice. To investigate self-renewal and multilineage
differentiation capacity of Pdk2/: Pdk4/ LT-HSCs, we
performed BM transplantation of these cells with congenic
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Figure 5. Defective Maintenance of Pdk2–/–: Pdk4–/– HSCs after Transplantation
(A) PB counts in control and Pdk2/: Pdk4/ mice (mean ± SD, n = 7).
(B) Colony-forming capacity of control (open bars) and Pdk2/: Pdk4/ LSK cells (closed bars) (mean ± SD, n = 3). CFU-GEMM, CFU-E, CFU-GM, and total
colony numbers are indicated.
(C) PB chimerism in primary BMT recipients of control (open boxes) or Pdk2/: Pdk4/ LT-HSC (closed boxes) cells at 1, 2, 3 and 4 months (M) after BMT
(mean ± SD, n = 10).
(D) Differentiation status (CD4/CD8+ T cells, B220+ B cells, or Mac-1/Gr-1+ myeloid cells) of donor-derived (Ly5.2+) PB cells in primary BMT recipients of control
(open bars) or Pdk2/: Pdk4/ (closed bars) LT-HSCs (mean ± SD, n = 10).
(E) Donor-derived (Ly5.2+) BMMNC, Lin, LSK, CD34Flt3 LSK, or SLAM-LSK chimerism in primary BMT recipients of control (open bars) or Pdk2/: Pdk4/
(closed bars) LT-HSCs 4 months after primary BMT (mean ± SEM, n = 10).
(F) PB chimerism in secondary recipients of BM derived from primary recipients of control (open boxes) or Pdk2/: Pdk4/ (closed boxes) MNCs, at indicated
times after BMT (mean ± SD, n = 10).
(G) Differentiation status (CD4/CD8+ T cells, B220+ B cells, or Mac-1/Gr-1+ myeloid cells) of donor-derived (Ly5.2+) PB cells in secondary BMT recipients of
control (open bars) or Pdk2/: Pdk4/ (closed bars) cells (mean ± SD, n = 10).
(H) Redox-sensitive MitoTracker fluorescence in control (open bars) or Pdk2/: Pdk4/ (closed bars) BM LT-HSCs (n = 3, mean ± SD).
(I) Quantitative PCR analysis of p16Ink4a expression in control (open bars) or Pdk2/: Pdk4/ (closed bars) donor-derived LT-HSCs 4months after primary BMT
(n = 4). Values are normalized to b-actin expression and expressed as fold induction compared to levels detected in HIF-1a+/+ Ly5.2+ LSK samples (mean ± SD).
See also Figure S5.
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HSC Metabolic Checkpoint by Pdkcompetitors into lethally irradiated recipient mice. In contrast to
the capacity of differentiated counterparts, LT-HSCs were
defective in repopulation of primary recipient peripheral blood
at 3–4 months after transplantation (Figure 5C). Four months
after BMT, Pdk2/: Pdk4/ donor-derived cells retained
differentiation capacity of T, B, and myeloid cells comparable
with control donor-derived cells (Figure 5D). At that time,recipients of Pdk2/: Pdk4/ donor cells exhibited less
chimerism than did recipients of control donor cells in the
LSK-gated, CD34Flt3 LSK-gated, or SLAM-LSK-gated frac-
tion of BM (Figure 5E), indicating that HSC levels decreased.
We then isolated and transplanted 1 3 106 primary donor-
derived MNCs into secondary recipients. We observed a clear
defect in long-term reconstitution ability of Pdk2/: Pdk4/Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc. 55
Figure 6. Loss of Cell Cycle Quiescence and Glycolytic Capacity in Pdk2–/–: Pdk4–/– HSCs
(A) Representative flow cytometric plot of Pyronin Y analysis in the LSK-gated fraction of control or Pdk2/: Pdk4/ BM MNCs.
(B) Summary of flow cytometric Pyronin Y analysis of CD34 LSK or CD34+ LSK fractions in control or Pdk2/: Pdk4/ BM MNCs (mean ± SD, n = 6).
(C) Design of short-term BrdU labeling assay in control or Pdk2/: Pdk4/ mice.
(D) Representative flow cytometric plot showing BrdU labeling of the LT-HSC-gated fraction from control or Pdk2/: Pdk4/ BMMNCs. Numbers indicate the
frequency of the BrdU+ fraction in LT-HSCs (mean ± SD, n = 3).
(E) Immunocytochemical staining for the phosphorylated S293 residue of PDH-E1a (green), Mitotracker DeepRed (red), and DAPI (blue) in control or Pdk2/:
Pdk4/ LT-HSCs.
(F) LDH activity in LT-HSCs from control orPdk2/: Pdk4/mice (mean ± SD, n = 4). Shown are arbitrary values calculated as the value relative to LDH activity in
the control LT-HSC fraction (set to 100).
(G) Intracellular pyruvate concentration in LT-HSCs from control or Pdk2/: Pdk4/mice (mean ± SD, n = 3). Shown are arbitrary values calculated as the value
relative to intracellular pyruvate levels in the control LT-HSC fraction (set to 100).
See also Figure S6.
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and S5F) without any differentiation defect 4 months after
secondary transplantation (Figure 5G). We isolated and trans-
planted 1 3 106 secondary donor-derived MNCs into tertiary
recipients. We observed no long-term reconstitution ability
of Pdk2/: Pdk4/ HSCs in the PB of tertiary recipients
(Figure S5G). ROS reportedly induces p16Ink4a expression
(Takahashi et al., 2006), and p16Ink4a enhances HSC aging56 Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc.(Janzen et al., 2006). We observed increased mitochondrial
ROS production in Pdk2/: Pdk4/ LT-HSCs (Figure 5H).
Thus, ROS-mediated senescence of Pdk2/: Pdk4/ LT-HSCs
could account for loss of stem cell properties through
p16Ink4a upregulation. In support of this idea, we detected
significantly elevated levels of p16Ink4a transcripts in Pdk2/:
Pdk4/ LT-HSCs from primary and secondary BMT recipients
(Figure 5I).
Figure 7. Modulation of HSC Cell Cycle Quiescence by a PDH Inhibitor
(A) Design of LT-HSC cultures treated with or without 1-AA for 2 weeks. Light microscopic data show colony morphology.
(B) Effect of 1-AA withdrawal on LT-HSCs after 2 weeks of treatment. Light microscopic colony morphology after 4 weeks of culture.
(C) Intracellular pyruvate concentrations in LT-HSCs treated with or without 1-AA for 4 days (mean ± SD, n = 3). Shown are arbitrary values calculated as the value
relative to intracellular pyruvate in the control LT-HSC fraction (set to 100).
(D) Flow cytometric analysis of LT-HSCs treated with or without 1-AA in vitro for 4 weeks. Numbers indicate the LT-HSC fraction in LSK cells (mean ± SD, n = 4).
(E) Quantitative PCR analysis of p16Ink4a expression in control (open bars) or 1-AA-treated (closed bars) LT-HSCs 2weeks after culture with or without 1-AA (n = 4).
Values are normalized to b-actin expression and expressed as fold induction compared to levels detected in control samples (mean ± SD).
(F–H) Quantification of total cells (F), LSK cells (G), or LT-HSCs (H) from LT-HSC-derived colonies in the absence (control) or presence of 1-AA for 4 weeks in vitro
(mean ± SD, n = 4).
(I) Donor-derived (Ly5.1+) PB chimerism in BMT recipients of control LT-HSCs or LT-HSCs treated with 1-AA for 4 weeks, at indicated times after BMT (mean ±
SD, n = 4–5).
See also Figure S7.
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and Metabolism
The pivotal role played by Pdk2 andPdk4 in LT-HSC senescence
during transplantation suggests that Pdk-mediated antagonism
of mitochondrial metabolism prevents LT-HSC senescence by
maintaining cell cycle quiescence. To test this hypothesis, we
examined cell cycle kinetics of the Pdk2/: Pdk4/ LT-HSCs
by multicolor flow cytometry. Although the number of LT-HSCs,
ST-HSCs, and MPPs was unchanged in Pdk2/: Pdk4/mice (Figures S5D and S5E), we detected specific activation of
the cell cycle, characterized by a reduction in the Pyronin Y
G0 fraction and an increase in the Pyronin Y+ G1 fraction, in
Pdk2/: Pdk4/ CD34 LSK cells (Figures 6A and 6B). Recip-
ient mice whose BM was replaced by Pdk2/: Pdk4/ MNCs
(Pdk2/: Pdk4/ BM mice) also showed similar loss of the G0
fraction in Pdk2/: Pdk4/ CD34 LSK cells (Figures S6A and
S6B). Interestingly, CD34+ LSK cells showed an increase in the
Pyronin Y G0 fraction in Pdk2/: Pdk4/ mice (bothCell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc. 57
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Pdk2/: Pdk4/), but not in Pdk2/: Pdk4/ BM mice
(Pdk2/: Pdk4/ hematopoietic cells and Pdk2+/+: Pdk4+/+
hematopoietic microenvironment) (Figures 6A, 6B, S6A, and
S6B). These observations suggest thatPdk2/: Pdk4/ nonhe-
matopoietic cells limit blood cell production by slowing the G0/
G1 progression of Pdk2/: Pdk4/ progenitors. Also, short-
term BrdU labeling indicated high levels of cycling cells in the
Pdk2/: Pdk4/ LT-HSC population (Figures 6C and 6D). In
addition to the cell cycle defect, we detected metabolic defects
in Pdk2/: Pdk4/ mice. In Pdk2/: Pdk4/ LT-HSCs, PDH-
E1a subunit phosphorylation status was decreased (Figures
6E, S6C, and S6D) and intracellular LDH activity and pyruvate
content were significantly attenuated (Figures 6F and 6G). These
findings indicate that Pdks are necessary to maintain cell cycle
quiescence and LT-HSC metabolic properties.
A Pdk Mimetic Modulates Cell Cycle Quiescence
in LT-HSCs
To determine whether metabolic reprogramming could be
achieved in HSCs, we artificially suppressed PDH activity using
the PDH inhibitor, 1-aminoethylphosphinic acid (1-AA). This
molecule is converted by aminotransferase to the pyruvate
analog acetylphosphinic acid, which competes with pyruvate
to suppress PDH enzymatic activity (Laber and Amrhein, 1987;
Nemeria et al., 2006). In vitro treatment of isolated LT-HSCs,
ST-HSCs, or MPPs with or without 1-AA for 2 weeks maintained
LT-HSCs and ST-HSCs (Figures 7A, S7A, and S7B). No viable
cells were detected in MPPs in the presence of 1-AA after
2 weeks of culture (Figure S7B). Colony growth of LT- or ST-
HSCs in the culture medium was suppressed by 1-AA in vitro
(Figure S7B). LT-HSCs cultured with 1-AA for 2 weeks could
proliferate again after removal of 1-AA (Figure 7B). Treatment
of LT-HSCs with 1-AA in vitro showed higher pyruvate levels
than nontreated LT-HSCs (Figure 7C). In vitro treatment of iso-
lated LT-HSCs, ST-HSCs, or MPPs with or without 1-AA for
4 weeks only maintained LT-HSCs (Figure S7C). No viable cells
were detected in ST-HSCs and MPPs in the presence of 1-AA
after 4 weeks of culture (Figures S7A and S7C). Colony growth
of LT-HSCs in the culture medium was suppressed by 1-AA
in vitro (Figure S7C). Flow cytometric analysis of LT-HSC-
derived colony after 4 weeks of culture revealed preferential
maintenance of LT-HSC frequency within LSK cells in the pres-
ence of 1-AA compared to control cells (Figure 7D). LT-HSCs
treated with 1-AA for 2 weeks lacked expression of p16Ink4a
mRNA in LT-HSCs (Figure 7E). Both the total number of cells
and that of LSK cells were suppressed by 1-AA treatment
after 4 weeks of culture (Figures 7F and 7G). In contrast, 1-AA
treatment maintained the LT-HSC fraction in vitro (Figure 7H).
Transplanted LT-HSC-derived colonies after 4 weeks of culture
retained reconstitution capacity of PB and BM during transplan-
tation (Figures 7I and S7D). These data collectively suggest that
metabolic reprogramming by Pdk induction could be a potent
tool to modulate the cell cycle of LT-HSCs.
DISCUSSION
The present study provides direct evidence for metabolic
specificity of LT-HSCs compared to progenitors or terminally58 Cell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc.differentiated cells. Our observations indicate that LT-HSCs
specifically activate glycolysis and suppress influx of glycolytic
metabolites into mitochondria via Pdk activity. We also demon-
strate the importance of glycolytic ATP production promoted
by the HIF-1a/Pdk regulatory system for HSC stem cell capacity
bymaintaining cell cycle quiescence. In lower eukaryotes, quies-
cence is defined not only in terms of the cell cycle but as a meta-
bolically specific state characterized by suppressed catabolism
and resulting in a nondividing phase (Allen et al., 2006; Klosinska
et al., 2011; Laporte et al., 2011). Establishment of cell cycle
quiescence via altered metabolic activity is an effective strategy
to survive extreme conditions of starvation or hypoxia.
Our initial metabolomics analysis of purified HSCs, progeni-
tors, and terminally differentiated cells using CE-TOFMS indi-
cated that quiescent LT-HSCs exhibit specific carbon metabo-
lism phenotypes favoring glycolysis (Figures 1A and S1A). Low
ATP levels generated in LSK fraction subpopulations, which are
maintained by glycolysis, gradually increase during differentia-
tion from LT-HSCs to MPPs through ST-HSCs (Figure 1B). Like-
wise, various glycolytic regulators are highly expressed in LT-
HSCs in a HIF-1a-dependent manner. Among these regulators,
levels of Pdk2 and Pdk4 are regulated by HIF-1a levels. Pdk
actively suppresses mitochondrial metabolism and maintains
ATP generation during hypoxia through PDH-E1a phosphoryla-
tion (Harris et al., 2002). Pdk1 is reportedly a direct HIF-1a target
in murine embryonic fibroblasts and human solid tumor cell lines
(Kim et al., 2006; Papandreou et al., 2006). Our data suggest that
Pdk2 and Pdk4 are downstream effectors of HIF-1a in maintain-
ing LT-HSC cell cycle quiescence. Rescue ofHIF-1aD/DHSCs by
Pdk overexpression as well as loss-of-function experiments in
HSCs from Pdk2/: Pdk4/ mice indicate an important role
for Pdks onLT-HSCcell cycle quiescence in aHIF-1a-dependent
manner. Therefore, Pdk probably functions in two ways, via
activation of glycolysis and suppression of influx of glycolytic
metabolites intomitochondria, tomaintain LT-HSCs in a hypoxic,
hypoperfused, and low-nutrient niche in the BM. Metabolic
activities demonstrated here may also protect HSCs from ROS
generation either through mitochondria or through accelerated
consumption of NADH by LDH activity, which would ameliorate
oxidative stress (Suematsu et al., 1992). In addition, products of
the TCA cycle, including citrate, could return to the cytosol to
drive lipid metabolism required for cell growth and proliferation
(Lum et al., 2007). Thus, Pdk could suppress mitochondrial
ROS generation and decrease the lipid supply to modulate
cellular proliferation. The characteristic metabolite pool in LT-
HSCs may also activate a signaling pathway favoring quies-
cence. Because the Pdk mimetic 1-AA induced increased levels
of pyruvate and enhanced LT-HSC maintenance via cell cycle
quiescence in vitro, suppression of glycolytic metabolic influx
into mitochondria and activation of glycolysis via the HIF-1a/
Pdk system could be the primary event in generating HSC quies-
cence. Activation of a Pdk/PDH checkpoint results in a decou-
pling of glycolysis and the mitochondrial TCA cycle and might
confer a metabolic robustness through two independent energy
factories—glycolysis and TCA cycle—in LT-HSCs. Although 1-
AA induced ST-HSC cell cycle suppression and maintained cells
for 2 weeks, they died in vitro after 4 weeks in culture. Therefore,
cell cycle suppression via the PDH may function not only in LT-
HSCs but also in differentiated ST-HSCs, although additional
Cell Stem Cell
HSC Metabolic Checkpoint by Pdkmetabolic programs may also maintain ST-HSCs. In addition,
1-AA treatment not only supported the cell number of LT-HSCs
but also had a qualitative effect on transplantation capacity of
LT-HSCs, as shown in Figures 7I and S7D. Overall, suppression
of mitochondrial metabolite flux by Pdks is an efficient strategy
for stem cell maintenance. This observation is in contrast to the
activity of cancer cells, which utilize aerobic glycolysis and
suppress mitochondrial metabolism to promote proliferation
rather than quiescence (DeBerardinis et al., 2008; Jones and
Thompson, 2009). Thus, the existence of differing molecular
mechanisms underlying identical metabolic phenotypes may
suggest strategies for novel tumor-specific therapy.
Although we could rule out the importance of other Pdks,
including Pdk1 and Pdk3, on HIF-1aD/D HSCs, it is noteworthy
thatHIF-1aD/D LT-HSCs, which show decreased Pdk2/4 expres-
sion, exhibit decreased phosphorylation of PDH-E1a and
increased mitochondrial size. These size changes may be due
to HIF-1a-regulated increases in mitochondrial biogenesis
(Zhang et al., 2007) or reduced mitochondrial autophagy (Zhang
et al., 2008). However, reduced ATP content resulting from
attenuated glycolysis, a hallmark of senescent cells (Zwerschke
et al., 2003), seen inHIF-1aD/D LT-HSCs could not be rescued by
mitochondrial ATP generation (Figure 3F), suggesting an essen-
tial role for anaerobic glycolysis in energy production by hypoxic
HSCs. Because VHLD/D LSK cells show decreased mitochon-
drial content, mitochondrial mass is probably also regulated by
the VHL/HIF-1a regulatory system in HSCs and progenitors.
Various studies of HSCs defective in ATP generation indicate
that LT-HSCs exhibit mitochondrial defects (Liu et al., 2009; Na-
kada et al., 2010; Gurumurthy et al., 2010; Gan et al., 2010; Sahin
et al., 2011). Therefore, although influx of glycolytic metabolites
into mitochondria is suppressed by Pdks, mitochondrial meta-
bolic integrity is apparently important for LT-HSC maintenance.
The elucidation of these integrative metabolic programs in LT-
HSCs extends the concept of the stem cell niche and suggests
a strategy for maintaining and expanding HSC resources by
modulating their quiescence via Pdk/PDH modulators or
enhancement of HIF-1a signaling.
EXPERIMENTAL PROCEDURES
CE-TOFMS Analysis
For CE-TOFMS analysis, BM cells including CD34Flt3 LSK (LT-HSCs),
CD34+Flt3 LSK (ST-HSCs), CD34+Flt3+ LSK (MPPs), Lin c-Kit+ Sca-1
(MPs), Gr-1/Mac-1+ (myeloid cells), CD4/CD8+ (T cells), and B220+ (B cells)
(1–2 3 106 cells) sorted from 120 C57BL/6 mice (12 weeks old) were lysed
to extract metabolites. Metabolomic profiling and data analysis were per-
formed twice essentially as described (Soga et al., 2003, 2006).
Mice
Mx1-cre:HIF-1a flox/flox,Mx1-cre:VHLflox/flox or Pdk2/: Pdk4/mice (Takubo
et al., 2010; Dunford et al., 2011; Jeoung et al., 2006) were genotyped using
PCR-based assays of tail DNA samples. To prepare HIF-1aD/D mice, we
induced Mx1-cre expression by intraperitoneal injection of 400 mg of pIpC
(Amersham or Sigma) into 4- to 8-week-old mice on 3 alternate days. Age-
matched pIpC-injected Mx1-cre:HIF-1a+/+ mice or Cre(-):HIF-1a flox/flox mice
served as controls (HIF-1a+/+ mice). C57BL/6-Ly5.1 congenic or C57BL/6-
Ly5.1/Ly5.2 F1 mice were used for competitive repopulation assays. To
preparemicewithVHLD/D,HIF-1aD/D:VHLD/D orPdk2/: Pdk4/BM (VHLD/D,
HIF-1aD/D:VHLD/D orPdk2/: Pdk4/BMmice), we transplanted 63 106–13
107 BM MNCs or CD45+ BM MNCs from Mx1-cre:VHLflox/flox or Mx1-cre:HIF-
1a flox/flox: VHLflox/flox mice into lethally irradiated C57BL/6-Ly5.1 mice. Sixweeks after BMT, we checked for peripheral blood chimerism and utilized
recipients with more than 90% donor-derived cells. Cre expression in replaced
BM was induced by intraperitoneal injection of 250 mg of pIpC (Amersham or
Sigma) on 3 alternate days. Mx1-cre:HIF-1a+/+:VHL+/+ or Pdk2+/+: Pdk4+/+
BM mice served as controls.
Antibodies
The following monoclonal antibodies (mAbs) were used in this study: rat
mAbs against c-Kit (2B8), Sca-1 (E13-161.7), CD4 (L3T4), CD8 (53-6.72),
B220 (RA3-6B2), TER-119, Gr-1 (RB6-8C5), CD34 (RAM34), Mac-1 (M1/70),
CD3 (500A2), Flt-3 (A2F10.1), CD41 (MWReg30), CD48 (HM48-1), CD150
(TC15-12F12.2), CD45.2 (104), and CD45.1 (A20). All rat mAbswere purchased
from BD, eBiosciences, or Biolegend. A mixture of mAbs against CD4, CD8,
B220, TER-119, Mac-1, and Gr-1 was used as a lineage marker (Lineage).
We also utilized anti-Ki67 (SP-6, Labvision), anti-PDH-E1a (pSer293) (Merck),
anti-PDH-E1a (pSer300) (Merck), and anti-COX4-1 (MitoSciences) antibodies
for immunocytochemical experiments.
Flow Cytometry
Analysis of various HSC fractions, detection of Side Population by Hoechst
33342, and Pyronin Y analysis were performed essentially as described (Arai
et al., 2004). For flow cytometry analysis of metabolic properties of quiescent
stem cells, we pretreated BM MNCs in vitro with 2-DG and/or NaN3 10 min
before staining with Hoechst 33342. For flow cytometric analysis of glucose
uptake, BM cells were isolated and preincubated for 30 min at 37C
with 2-[N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino]-2-Deoxy-D-Glucose or
2-[N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino]-2-Deoxy-L-Glucose (negative
control) (Peptide Institute) before staining with surface markers. For intracel-
lular flow cytometry analysis of phosphorylated PDH-E1aS293, cells were fixed
and permeabilized as previously described (Takubo et al., 2010) and stained
with anti-phosphorylated pPDH-E1aS293 antibody and a fluorophore-labeled
secondary antibody.
Immunocytochemistry
Immunocytochemistry of isolated cells was performed as described (Takubo
et al., 2008). In brief, cells were attached to glass slides and fixed with 4%
PFA. Slides were then blocked with a protein blocker (DAKO) to avoid nonspe-
cific staining. Specimens were reacted with primary antibodies followed by
fluorophore-labeled secondary antibodies and nuclear staining.
Cell Cycle Analysis
For immunocytochemical analysis, Ki67+ cells were detected with an anti-Ki67
antibody (SP-6) followed by incubation with a fluorophore-labeled anti-rabbit
Ig antibody (MolecularProbes). The cutoff range for fluorescence was deter-
mined by a negative control sample stained with an isotype control Ig followed
by secondary Ab treatment. The proportion of Ki67-positive cells in each frac-
tion was determined by counting. At least 500 cells per sample were examined
for each specimen. For FACS analysis of the cell cycle, cells were first stained
with antibodies for surfacemarkers and then fixed and permeabilized to detect
the intracellular BrdU with BrdU Flow Kit (Beckman Coulter).
Analysis of Mitochondrial Mass and ROS Production
For confocal microscopy of mitochondria, sorted cells were stained with anti-
COX4-1 antibody or incubated for 30 min at 37C with 100 nM mitotracker
Deep Red (MolecularProbes), which binds to mitochondrial membranes inde-
pendent of membrane potential. Stained cells were attached to glass slides
and counterstained with TOTO-3 or DAPI (MolecularProbes) for 30 min.
Samples were then three-dimensionally analyzed by laser confocal micros-
copy for the relative mitochondrial volume of individual cells under identical
acquisition settings in the linear range of the acquired fluorescence. We
randomly chose cells in multiple fields (more than five fields per sample). Mito-
chondrial fluorescence was normalized to nuclear DNA fluorescence. To
detect mitochondrial ROS production, we stained sorted cells with 100 nM
Mitotracker Orange CMH2TMROS (MolecularProbes) for 30 min at 37
C and
analyzed them by FACS.
Quantitative RT-PCR
Quantitative PCR was performed as described previously (Takubo et al.,
2008). The cDNA equivalent of 500 cells per reaction was used as a templateCell Stem Cell 12, 49–61, January 3, 2013 ª2013 Elsevier Inc. 59
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KaRa Bio.
Virus Transduction
For retrovirus transduction, murine Pdk2 and Pdk4 cDNAs were subcloned
upstream of IRES-EGFP in pMY-IRES-EGFP (Nosaka et al., 1999). To produce
recombinant retrovirus, we transfected plasmid DNA into Plat-E cells by
FuGENE (Roche). Supernatants of transfected cells were used to transduce
LSK cells or LT-HSCs precultured with SCF and thrombopoietin (TPO) for
16 hr. At 48 hr posttransduction, GFP+ cells were sorted by FACS and
analyzed, transplanted, or cultured for assays.
Serum-free HSC Culture
Sorted cells were cultured on U-bottomed fibronectin-coated plates.
Cultures were maintained in SF-O3 medium (Sanko Junyaku) containing
1.0% BSA, 100 ng/ml SCF, 100 ng/ml TPO with or without 1-AA. After 14 or
28 days of cultivation, cells were collected, stained with fluorophore-labeled
mAb, and analyzed by FACS or used for immunocytochemical and metabolic
analysis.
Bone Marrow Transplant
For Pdk rescue experiments, transduced GFP+ LSK cells from HIF-1a+/+
or HIF-1aD/D mice (Ly5.2), together with 4 3 105 BM MNCs from C57BL/
6-Ly5.1 mice, were transplanted into lethally irradiated C57BL/6-Ly5.1 con-
genic mice. For Pdk2/: Pdk4/ mice, 500 CD34Flt3 LSK cells from
Pdk2+/+: Pdk4+/+ or Pdk2/: Pdk4/ mice (Ly5.2), together with 4 3 105
BM MNCs from C57BL/6-Ly5.1 mice, were transplanted into lethally
irradiated C57BL/6-Ly5.1 congenic mice. For 1-AA treatment, 830 CD34
Flt3 LSK cells from C57BL/6-Ly5.1 mice were cultured in SF-O3 medium
containing 1.0% BSA, 100 ng/ml SCF, 100 ng/ml TPO with or without 1-AA
and the colony derived from 830 CD34Flt3 LSK cells at day 28 was
harvested and transplanted into lethally irradiated C57BL/6 mice (Ly5.2)
with 4 3 105 BM MNCs from C57BL/6 mice. One, two, three, and four
months after BMT, peripheral blood was collected and examined to
determine the percentage of donor-derived cells and the differentiation status
of donor-derived cells by FACS. Four months after BMT, BM MNCs were
collected and examined to determine the percentage of donor-derived cells
by FACS.
Determination of Intracellular ATP, LDH Activity, Pyruvate Content,
and PK Activity
Sorted cells (1–5 3 104) were lysed, and intracellular ATP, LDH activity, pyru-
vate content, or PK activity was measured using the Luciferase ATP Determi-
nation Kit (Sigma), the LDH Cytotoxicity Detection Kit (TaKaRa), the Pyruvate
Assay Kit (BioVision), or the Pyruvate Kinase Activity Assay Kit (BioVision),
respectively, following the manufacturers’ instructions.
OCR Determination
Sorted cells (5 3 104) were attached to the bottom of a XF96 Tissue Culture
Plate (Seahorse Bioscience) coated with BD Cell-Tak Cell Adhesive. Then,
cells were incubated in the presence of SCF and TPO with or without oligomy-
cin and OCR was measured by XF96 Extracellular Flux Analyzer (Seahorse
Bioscience).
Analysis of HSC Lactate Production
Sorted cells (1–5 3 104) were cultured under normoxic or hypoxic conditions
for 26 hr. Culture supernatants were then analyzed using the Lactate Assay
Kit (BioVision) following the manufacturer’s instructions.
Statistical Analysis
Data are presented as means ± SD unless stated otherwise. Statistical signif-
icancewas determined by Tukey’s multiple comparison test. To compare two-
group experiments, we used the two-tailed Student’s t test.
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